

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA ISOTOPE & RADIATION CORPORATION

中國同輻股份有限公司

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1763)

VOLUNTARY ANNOUNCEMENT ENTERING INTO EQUITY TRANSFER AGREEMENT TO FURTHER EXPAND THE NON-DESTRUCTIVE TESTING BUSINESS LAYOUT

This announcement is made on a voluntary basis by China Isotope & Radiation Corporation (“CIRC” or the “**Company**”) to keep shareholders and potential investors informed of the latest business developments of the Company.

The board of directors of the Company is pleased to announce that on 19 March, Chengdu Gaotong Isotope Co., Ltd. (CNNC) (成都中核高通同位素股份有限公司) (“**CNGT**”), a subsidiary of CIRC, entered into an equity transfer agreement to acquire 51% equity interest of Hunan Huifeng Engineering Detection Co., Ltd. (湖南滙豐工程檢測有限公司) (“**Huifeng Detection**”). Upon completion of the transaction, Huifeng Detection will become a controlling subsidiary of the Company and will be consolidated into the consolidated statements.

Huifeng Detection is mainly engaged in special equipment inspection and testing services and is one of the institutions with relatively comprehensive qualifications and a higher level in the national special equipment non-destructive testing industry, possessing 9 complete qualifications under the inspection and testing institution approval certificate of special equipment of the People's Republic of China: four types of CG basic testing including “radiographic testing (RT), ultrasonic testing (UT), penetrant testing (PT) and magnetic particle testing (MT)”, eddy current testing (ECT), acoustic emission (AE) testing, time of flight diffraction (TOFD), phased array ultrasonic testing (PAUT), magnetic flux leakage (MFL) (including magnetic flux leakage of tank bottom plates, internal and external magnetic flux leakage of pipelines); periodic inspection of public pipelines (DD2) and periodic inspection of industrial pipelines (DD3); safety valve calibration; as well as the CMA qualification certificate for inspection and testing institutions, the laboratory accreditation certificate from the China National Accreditation Service for Conformity Assessment (CNAS) and a comprehensive operation management system. It has a broad customer base in the fields of petrochemicals, metallurgy, aerospace, rail transit and electric power, with its business network covering most regions of China.

Anchoring on the positioning of “a world-class system integration supplier of radioactive sources and application technology”, CNGT focuses on four directions including isotopes, radioactive sources, equipment containing radioactive sources and application services for equipment containing radioactive sources, and is committed to building a full-chain industrial ecosystem of “radioactive source – equipment containing radioactive sources – back-end service”. CNGT occupies a dominant position in the domestic non-destructive testing radioactive source market and holds the vast majority of the market share. This transaction represents another expansion of the non-destructive testing business layout by CNGT since the acquisition of Xi'an Zhanshi Testing & Engineering Co., Ltd. (西安展實檢測工程有限公司) in 2023, and will assist it in further expanding its market share in segmented areas, enhancing its comprehensive competitive strength, and steadily elevating its market position and core influence in the industry.

By order of the Board
China Isotope & Radiation Corporation
Xiao Yafei
Chairman

Beijing, the PRC, 19 March 2026

As at the date of this announcement, the Board comprises Mr. Xiao Yafei, Mr. Zhang Junqi, Ms. Huo Yingying and Ms. Ma Xiaoyu as executive Directors; Mr. Chen Zan, Mr. Ding Jianmin and Ms. Chang Jinyu as non-executive Directors; and Mr. Poon Chiu Kwok, Ms. Chen Jingshan, Mr. Lu Chuang and Mr. An Rui as independent non-executive Directors.